| 154.85 -4.31 (-2.71%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 198.16 | 1-year : | 214.52 |
| Resists | First : | 169.66 | Second : | 183.66 |
| Pivot price | 163.43 |
|||
| Supports | First : | 147 | Second : | 122.3 |
| MAs | MA(5) : | 158.05 |
MA(20) : | 166.25 |
| MA(100) : | 165.2  |
MA(250) : | 112.49 |
|
| MACD | MACD : | -2.6 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 7.8 |
D(3) : | 10.3 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 200 | Low : | 56.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BLTE ] has closed above bottom band by 10.9%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 160.43 - 161.21 | 161.21 - 161.98 |
| Low: | 151.5 - 152.46 | 152.46 - 153.41 |
| Close: | 153.06 - 154.59 | 154.59 - 156.1 |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Sun, 03 May 2026
BLTE SEC Filings - Belite Bio, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sun, 03 May 2026
Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission - Yahoo Finance
Sun, 03 May 2026
BLTE SEC Filings - Belite Bio, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 01 May 2026
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Fri, 01 May 2026
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Fri, 01 May 2026
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 43.8 (%) |
| Held by Institutions | 18.5 (%) |
| Shares Short | 1,040 (K) |
| Shares Short P.Month | 792 (K) |
| EPS | -2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.3 % |
| Return on Equity (ttm) | -17 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -66.75 |
| PEG Ratio | 0 |
| Price to Book value | 7.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -167.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|